Short Interest in Hologic, Inc. (NASDAQ:HOLX) Increases By 5.1%

Hologic, Inc. (NASDAQ:HOLX) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,810,000 shares, an increase of 5.1% from the September 30th total of 5,530,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is presently 3.9 days. Currently, 2.5% of the shares of the company are sold short.

Hologic Trading Up 1.8 %

Shares of Hologic stock opened at $82.33 on Friday. Hologic has a 12-month low of $66.53 and a 12-month high of $84.67. The stock has a market capitalization of $19.12 billion, a P/E ratio of 28.00, a price-to-earnings-growth ratio of 2.94 and a beta of 0.98. The company has a 50-day simple moving average of $80.99 and a 200 day simple moving average of $77.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Wall Street Analyst Weigh In

HOLX has been the topic of several research analyst reports. Evercore ISI raised their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Mizuho upped their price target on Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 4th. JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Finally, Leerink Partners cut their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $87.50.

Insider Activity

In related news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hologic

Hedge funds and other institutional investors have recently bought and sold shares of the business. Norden Group LLC increased its stake in shares of Hologic by 2,217.0% in the first quarter. Norden Group LLC now owns 88,160 shares of the medical equipment provider’s stock valued at $6,873,000 after buying an additional 84,355 shares in the last quarter. First Trust Direct Indexing L.P. raised its stake in shares of Hologic by 3.3% in the first quarter. First Trust Direct Indexing L.P. now owns 7,882 shares of the medical equipment provider’s stock worth $614,000 after acquiring an additional 253 shares during the last quarter. Legacy Wealth Asset Management LLC lifted its position in shares of Hologic by 16.8% during the first quarter. Legacy Wealth Asset Management LLC now owns 3,650 shares of the medical equipment provider’s stock worth $285,000 after purchasing an additional 526 shares in the last quarter. Leeward Investments LLC MA lifted its position in shares of Hologic by 112.1% during the first quarter. Leeward Investments LLC MA now owns 166,521 shares of the medical equipment provider’s stock worth $12,982,000 after purchasing an additional 87,999 shares in the last quarter. Finally, HB Wealth Management LLC grew its stake in shares of Hologic by 8.6% during the first quarter. HB Wealth Management LLC now owns 5,463 shares of the medical equipment provider’s stock valued at $426,000 after purchasing an additional 431 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.